UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 16, 2020
TAURIGA SCIENCES, INC.
(Exact name of registrant as specified in its charter)
| Florida | 000-53723 | 30-0791746 | ||
(State or other jurisdiction of incorporation) |
(Commission File #) |
(IRS Employer Identification Number) |
555 Madison Avenue, 5th Floor
New York, NY
(Address of principal executive office)
Tel: (917) 796-9926
(Registrant’s telephone number)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
| Common Stock, par value $0.00001 per share | TAUG | OTCQB |
| Item 8.01 | Other Events. |
On January 23, 2020, the Company issued a press release announcing that it had entered into a $5,000,000 equity line of credit (“ELOC”) financing pursuant to the terms of an investment and registration rights agreement with Tangiers Global, LLC, pursuant to which we filed a resale registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”) to register seventy six million shares of our common stock. The registration statement was declared effective on March 16, 2020 by the SEC.
Additionally, on April 3, 2020, the Company entered into a collaboration agreement with Aegea Biotechnologies Inc. for the purpose of developing a Rapid, Multiplexed Novel Coronavirus (COVID-19) Point of Care Test with Superior Sensitivity and Selectivity (the “SARS-Col 2 Test”), which was reported on our current Report on Form 8-K on April 15, 2020.
As of the date of this report, the Company has contributed a total of $183,442.00 towards this collaboration agreement, a portion of which was funded through the sale of our common stock under our existing ELOC. To date, we have issued a total of 5,750,000 shares of our common stock under our ELOC, and there remains available for future issuance thereunder 70,250,000 shares.
We will provide additional periodic updates on these and other material business items in the ordinary course of business, either via press release or in our current or quarterly reports, as applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 17, 2020
| TAURIGA SCIENCES, INC. | ||
| By: | /s/ Seth M. Shaw | |
| Seth M. Shaw | ||
| Chief Executive Officer | ||